{
    "nct_id": "NCT02240693",
    "title": "A Multi-centre, Double-blind, Parallel-group, Randomized Controlled Study to Investigate the Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Alzheimer Disease",
    "status": "COMPLETED",
    "last_update_time": "2018-10-31",
    "description_brief": "The study is designed to compare the effects of 4 different doses of orally administered BI 409306 to placebo in patients with Alzheimers Disease",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "preAssignmentDetails": "For this trial, patients were randomised at 36 sites in 11 countries. Following an initial Screening Visit and a single blinded 2-week placebo run-in period, patients who qualified according to the in- and exclusion criteria were randomised to one of the five treatment groups",
            "recruitmentDetails": "A multi-centre, double-blind, parallel-group, randomized controlled study to investigate the efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared to placebo in patients with Alzheimer's Disease",
            "groups": [
                {
                    "id": "FG000",
                    "title": "BI 409306 10 Milligram (mg) Once Daily (QD)",
                    "description": "Patients were administered orally a tablet of 10 mg BI 409306 once daily for 12 weeks."
                },
                {
                    "id": "FG001",
                    "title": "BI 409306 25 mg QD",
                    "description": "Patients were administered orally a tablet of 25 mg BI 409306 once daily for 12 weeks."
                },
                {
                    "id": "FG002",
                    "title": "BI 409306 50 mg QD",
                    "description": "Patients were administered orally a tablet of 50 mg BI 409306 once daily for 12 weeks."
                },
                {
                    "id": "FG003",
                    "title": "BI 409306 25 mg Twice Daily (BID)",
                    "description": "Patients were administered orally a tablet of 25 mg BI 409306 twice daily for 12 weeks."
                },
                {
                    "id": "FG004",
                    "title": "Placebo Matching BI 409306",
                    "description": "Patients were administered orally Placebo matching 10 mg/25 mg/ 50 mg BI 409306 for 12 weeks"
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "22"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "21"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "21"
                                },
                                {
                                    "groupId": "FG003",
                                    "numSubjects": "21"
                                },
                                {
                                    "groupId": "FG004",
                                    "numSubjects": "43"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "22"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "21"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "17"
                                },
                                {
                                    "groupId": "FG003",
                                    "numSubjects": "20"
                                },
                                {
                                    "groupId": "FG004",
                                    "numSubjects": "42"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "4"
                                },
                                {
                                    "groupId": "FG003",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG004",
                                    "numSubjects": "1"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Adverse Event",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG003",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG004",
                                    "numSubjects": "1"
                                }
                            ]
                        },
                        {
                            "type": "Withdrawal by Subject",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "2"
                                },
                                {
                                    "groupId": "FG003",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG004",
                                    "numSubjects": "0"
                                }
                            ]
                        },
                        {
                            "type": "Other than specified",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "2"
                                },
                                {
                                    "groupId": "FG003",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG004",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "populationDescription": "Treated set:\n\nThe treated set (TS) included all patients who were randomised and treated with at least one dose of trial medication.",
            "groups": [
                {
                    "id": "BG000",
                    "title": "BI 409306 10 Milligram (mg) Once Daily (QD)",
                    "description": "Patients were administered orally a tablet of 10 mg BI 409306 once daily for 12 weeks."
                },
                {
                    "id": "BG001",
                    "title": "BI 409306 25 mg QD",
                    "description": "Patients were administered orally a tablet of 25 mg BI 409306 once daily for 12 weeks."
                },
                {
                    "id": "BG002",
                    "title": "BI 409306 50 mg QD",
                    "description": "Patients were administered orally a tablet of 50 mg BI 409306 once daily for 12 weeks."
                },
                {
                    "id": "BG003",
                    "title": "BI 409306 25 mg Twice Daily (BID)",
                    "description": "Patients were administered orally a tablet of 25 mg BI 409306 twice daily for 12 weeks."
                },
                {
                    "id": "BG004",
                    "title": "Placebo Matching BI 409306",
                    "description": "Patients were administered orally Placebo matching 10 mg/25 mg/ 50 mg BI 409306 for 12 weeks"
                },
                {
                    "id": "BG005",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "22"
                        },
                        {
                            "groupId": "BG001",
                            "value": "21"
                        },
                        {
                            "groupId": "BG002",
                            "value": "21"
                        },
                        {
                            "groupId": "BG003",
                            "value": "21"
                        },
                        {
                            "groupId": "BG004",
                            "value": "43"
                        },
                        {
                            "groupId": "BG005",
                            "value": "128"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "72.3",
                                            "spread": "5.4"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "74.1",
                                            "spread": "8.1"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "73.3",
                                            "spread": "5.1"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "71.9",
                                            "spread": "6.0"
                                        },
                                        {
                                            "groupId": "BG004",
                                            "value": "72.2",
                                            "spread": "6.5"
                                        },
                                        {
                                            "groupId": "BG005",
                                            "value": "72.7",
                                            "spread": "6.3"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "10"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "12"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "8"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "13"
                                        },
                                        {
                                            "groupId": "BG004",
                                            "value": "28"
                                        },
                                        {
                                            "groupId": "BG005",
                                            "value": "71"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "12"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "9"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "13"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "8"
                                        },
                                        {
                                            "groupId": "BG004",
                                            "value": "15"
                                        },
                                        {
                                            "groupId": "BG005",
                                            "value": "57"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Race (NIH/OMB)",
                    "description": "Race data is presented below; Ethnicity was not reported in this trial",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "American Indian or Alaska Native",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG004",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG005",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Asian",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG004",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG005",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Native Hawaiian or Other Pacific Islander",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG004",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG005",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Black or African American",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG004",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG005",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "White",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "22"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "21"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "21"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "21"
                                        },
                                        {
                                            "groupId": "BG004",
                                            "value": "43"
                                        },
                                        {
                                            "groupId": "BG005",
                                            "value": "128"
                                        }
                                    ]
                                },
                                {
                                    "title": "More than one race",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG004",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG005",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Unknown or Not Reported",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG004",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG005",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Neuropsychological Test Battery (NTB) Total",
                    "description": "Baseline cognitive assessment data- NTB total z-score. The NTB consists of 9 validated components. Raw scores on each of the 9 NTB tests were converted to z-scores using the baseline means and standard deviations (SDs) for each test. The resultant z-scores were averaged to obtain a total z-score, incorporating all 9 NTB tests. The NTB Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean at baseline. Higher values indicate a better Outcome",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "z-score",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0.07",
                                            "spread": "0.70"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0.02",
                                            "spread": "0.75"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "-0.02",
                                            "spread": "0.72"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "-0.02",
                                            "spread": "0.61"
                                        },
                                        {
                                            "groupId": "BG004",
                                            "value": "-0.03",
                                            "spread": "0.63"
                                        },
                                        {
                                            "groupId": "BG005",
                                            "value": "-0.00",
                                            "spread": "0.66"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment.",
                    "description": "Neuropsychological Test Battery (NTB) response, defined as change from baseline in total z-score after 12 weeks of treatment. The NTB Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean at baseline. Negative numbers indicate values lower than baseline and positive numbers indicate values higher than baseline. Change from baseline will be calculated as the post-baseline composite z-score minus the pre-treatment z-score, such that a positive change indicates an improvement from baseline",
                    "populationDescription": "The full analysis set (FAS) included all randomised patients who were treated with at least one dose of trial medication and had a baseline and at least one post-baseline on-treatment efficacy assessment. Observed cases (OC)",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "z-score",
                    "timeFrame": "Baseline and 12 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "BI 409306 10 Milligram (mg) Once Daily (QD)",
                            "description": "Patients were administered orally a tablet of 10 mg BI 409306 once daily for 12 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "BI 409306 25 mg QD",
                            "description": "Patients were administered orally a tablet of 25 mg BI 409306 once daily for 12 weeks."
                        },
                        {
                            "id": "OG002",
                            "title": "BI 409306 50 mg QD",
                            "description": "Patients were administered orally a tablet of 50 mg BI 409306 once daily for 12 weeks."
                        },
                        {
                            "id": "OG003",
                            "title": "BI 409306 25 mg Twice Daily (BID)",
                            "description": "Patients were administered orally a tablet of 25 mg BI 409306 twice daily for 12 weeks."
                        },
                        {
                            "id": "OG004",
                            "title": "Pooled BI 409306",
                            "description": "Patients were administered orally a tablet of BI 409306 (10 mg, 25 mg, 50 mg once daily and 25 mg twice daily)for 12 weeks."
                        },
                        {
                            "id": "OG005",
                            "title": "Placebo Matching BI 409306",
                            "description": "Patients were administered orally Placebo matching 10 mg/25 mg/ 50 mg BI 409306 for 12 weeks"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "20"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "19"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "16"
                                },
                                {
                                    "groupId": "OG003",
                                    "value": "18"
                                },
                                {
                                    "groupId": "OG004",
                                    "value": "73"
                                },
                                {
                                    "groupId": "OG005",
                                    "value": "39"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.35",
                                            "spread": "0.061"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.20",
                                            "spread": "0.063"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "0.26",
                                            "spread": "0.065"
                                        },
                                        {
                                            "groupId": "OG003",
                                            "value": "0.32",
                                            "spread": "0.064"
                                        },
                                        {
                                            "groupId": "OG004",
                                            "value": "0.29",
                                            "spread": "0.031"
                                        },
                                        {
                                            "groupId": "OG005",
                                            "value": "0.27",
                                            "spread": "0.043"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG005"
                            ],
                            "groupDescription": "Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.",
                            "nonInferiorityType": "SUPERIORITY",
                            "nonInferiorityComment": "H0: The dose group with the peak response in the respective model Mean NTB response = Mean NTB response of placebo.",
                            "pValue": "0.3236",
                            "pValueComment": "p-value was nominal and not adjusted.",
                            "statisticalMethod": "Mixed Model Repeated Measurement (MMRM)",
                            "statisticalComment": "Kenward-Roger was used to model degrees of freedom.",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.07",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.074",
                            "ciUpperLimit": "0.223",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.075",
                            "estimateComment": "Mean difference (BI 409306 10 milligram (mg) once daily (QD) minus Placebo matching BI 409306)",
                            "otherAnalysisDescription": "The mean difference is actually adjusted mean of difference and the dispersion value is standard error of differences."
                        },
                        {
                            "groupIds": [
                                "OG001",
                                "OG005"
                            ],
                            "groupDescription": "Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.",
                            "nonInferiorityType": "SUPERIORITY",
                            "nonInferiorityComment": "H0: The dose group with the peak response in the respective model Mean NTB response = Mean NTB response of placebo.",
                            "pValue": "0.3694",
                            "pValueComment": "p-value was nominal and not adjusted.",
                            "statisticalMethod": "Mixed Model Repeated Measurement (MMRM)",
                            "statisticalComment": "Kenward-Roger was used to model degrees of freedom.",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.07",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.220",
                            "ciUpperLimit": "0.082",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.076",
                            "estimateComment": "Mean difference (BI 409306 25 mg QD minus Placebo matching BI 409306)",
                            "otherAnalysisDescription": "The mean difference is actually adjusted mean of difference and the dispersion value is standard error of differences."
                        },
                        {
                            "groupIds": [
                                "OG002",
                                "OG005"
                            ],
                            "groupDescription": "Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.",
                            "nonInferiorityType": "SUPERIORITY",
                            "nonInferiorityComment": "H0: The dose group with the peak response in the respective model Mean NTB response = Mean NTB response of placebo.",
                            "pValue": "0.8374",
                            "pValueComment": "p-value was nominal and not adjusted.",
                            "statisticalMethod": "Mixed Model Repeated Measurement (MMRM)",
                            "statisticalComment": "Kenward-Roger was used to model degrees of freedom.",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.02",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.171",
                            "ciUpperLimit": "0.139",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.078",
                            "estimateComment": "Mean difference (BI 409306 50 mg QD minus Placebo matching BI 409306)",
                            "otherAnalysisDescription": "The mean difference is actually adjusted mean of difference and the dispersion value is standard error of differences"
                        },
                        {
                            "groupIds": [
                                "OG003",
                                "OG005"
                            ],
                            "groupDescription": "Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.",
                            "nonInferiorityType": "SUPERIORITY",
                            "nonInferiorityComment": "H0: The dose group with the peak response in the respective model Mean NTB response = Mean NTB response of placebo.",
                            "pValue": "0.5484",
                            "pValueComment": "p-value was nominal and not adjusted.",
                            "statisticalMethod": "Mixed Model Repeated Measurement (MMRM)",
                            "statisticalComment": "Kenward-Roger was used to model degrees of freedom.",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.05",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.106",
                            "ciUpperLimit": "0.199",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.077",
                            "estimateComment": "Mean difference (BI 409306 25 mg twice daily (BID) minus Placebo matching BI 409306)",
                            "otherAnalysisDescription": "The mean difference is actually adjusted mean of difference and the dispersion value is standard error of differences"
                        },
                        {
                            "groupIds": [
                                "OG004",
                                "OG005"
                            ],
                            "groupDescription": "Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.",
                            "nonInferiorityType": "SUPERIORITY",
                            "nonInferiorityComment": "H0: The dose group with the peak response in the respective model Mean NTB response = Mean NTB response of placebo.",
                            "pValue": "0.7905",
                            "pValueComment": "p-value was nominal and not adjusted.",
                            "statisticalMethod": "Mixed Model Repeated Measurement (MMRM)",
                            "statisticalComment": "Kenward-Roger was used to model degrees of freedom.",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.01",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.092",
                            "ciUpperLimit": "0.121",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.054",
                            "estimateComment": "Mean difference (Pooled BI 409306 minus Placebo matching BI 409306)",
                            "otherAnalysisDescription": "The mean difference is actually adjusted mean of difference and the dispersion value is standard error of differences"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in ADCS-MCI-ADL (Alzheimer's Disease Cooperative Study/Activities of Daily Living for Patients With Mild Cognitive Impairment) Total Score After 12-week Treatment",
                    "description": "Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) is a rating scale used to assess basic and instrumental activities of daily living. In the full version of the scale, 23 items are rated by the investigator using information supplied by the caregiver.\n\nEach item has a score range varying from 0-3 to 0-5. The sum score can range from 0 to 78. Higher scores indicate better function.\n\nLeast Squares Mean is actually an adjusted mean change from baseline.",
                    "populationDescription": "FAS- Observed cases",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Unit on scale",
                    "timeFrame": "Baseline and 12 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "BI 409306 10 Milligram (mg) Once Daily (QD)",
                            "description": "Patients were administered orally a tablet of 10 mg BI 409306 once daily for 12 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "BI 409306 25 mg QD",
                            "description": "Patients were administered orally a tablet of 25 mg BI 409306 once daily for 12 weeks."
                        },
                        {
                            "id": "OG002",
                            "title": "BI 409306 50 mg QD",
                            "description": "Patients were administered orally a tablet of 50 mg BI 409306 once daily for 12 weeks."
                        },
                        {
                            "id": "OG003",
                            "title": "BI 409306 25 mg Twice Daily (BID)",
                            "description": "Patients were administered orally a tablet of 25 mg BI 409306 twice daily for 12 weeks."
                        },
                        {
                            "id": "OG004",
                            "title": "Placebo Matching BI 409306",
                            "description": "Patients were administered orally Placebo matching 10 mg/25 mg/ 50 mg BI 409306 for 12 weeks"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "19"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "18"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "20"
                                },
                                {
                                    "groupId": "OG003",
                                    "value": "17"
                                },
                                {
                                    "groupId": "OG004",
                                    "value": "37"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.24",
                                            "spread": "0.896"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "1.79",
                                            "spread": "0.921"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "-0.10",
                                            "spread": "0.875"
                                        },
                                        {
                                            "groupId": "OG003",
                                            "value": "0.80",
                                            "spread": "0.947"
                                        },
                                        {
                                            "groupId": "OG004",
                                            "value": "0.38",
                                            "spread": "0.642"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG004"
                            ],
                            "groupDescription": "The dependent variable was the change from the baseline score at Week 12. The model included fixed, categorical covariates of treatment as well as fixed continuous covariates of baseline score.",
                            "nonInferiorityType": "SUPERIORITY",
                            "nonInferiorityComment": "Analyses of covariance (ANCOVA) were used to assess between-group differences in the modelled changes from baseline to Week 12.",
                            "pValue": "0.8973",
                            "pValueComment": "p-value was nominal and not adjusted.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.14",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-2.33",
                            "ciUpperLimit": "2.04",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "1.102",
                            "estimateComment": "Mean difference (BI 409306 10 milligram (mg) once daily (QD) minus Placebo matching BI 409306)",
                            "otherAnalysisDescription": "The mean difference is actually adjusted mean of difference and the dispersion value is standard error of differences."
                        },
                        {
                            "groupIds": [
                                "OG001",
                                "OG004"
                            ],
                            "groupDescription": "The dependent variable was the change from the baseline score at Week 12. The model included fixed, categorical covariates of treatment as well as fixed continuous covariates of baseline score.",
                            "nonInferiorityType": "SUPERIORITY",
                            "nonInferiorityComment": "Analyses of covariance (ANCOVA) were used to assess between-group differences in the modelled changes from baseline to Week 12.",
                            "pValue": "0.2141",
                            "pValueComment": "p-value was nominal and not adjusted.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "1.40",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.82",
                            "ciUpperLimit": "3.63",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "1.122",
                            "estimateComment": "Mean difference (BI 409306 25 mg QD minus Placebo matching BI 409306)",
                            "otherAnalysisDescription": "The mean difference is actually adjusted mean of difference and the dispersion value is standard error of differences."
                        },
                        {
                            "groupIds": [
                                "OG002",
                                "OG004"
                            ],
                            "groupDescription": "The dependent variable was the change from the baseline score at Week 12. The model included fixed, categorical covariates of treatment as well as fixed continuous covariates of baseline score.",
                            "nonInferiorityType": "SUPERIORITY",
                            "nonInferiorityComment": "Analyses of covariance (ANCOVA) were used to assess between-group differences in the modelled changes from baseline to Week 12.",
                            "pValue": "0.6553",
                            "pValueComment": "p-value was nominal and not adjusted.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.49",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-2.64",
                            "ciUpperLimit": "1.67",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "1.085",
                            "estimateComment": "Mean difference (BI 409306 50 mg QD minus Placebo matching BI 409306)",
                            "otherAnalysisDescription": "The mean difference is actually adjusted mean of difference and the dispersion value is standard error of differences"
                        },
                        {
                            "groupIds": [
                                "OG003",
                                "OG004"
                            ],
                            "groupDescription": "The dependent variable was the change from the baseline score at Week 12. The model included fixed, categorical covariates of treatment as well as fixed continuous covariates of baseline score.",
                            "nonInferiorityType": "SUPERIORITY",
                            "nonInferiorityComment": "Analyses of covariance (ANCOVA) were used to assess between-group differences in the modelled changes from baseline to Week 12.",
                            "pValue": "0.7166",
                            "pValueComment": "p-value was nominal and not adjusted.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.42",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-1.85",
                            "ciUpperLimit": "2.69",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "1.144",
                            "estimateComment": "Mean difference (BI 409306 25 mg twice daily (BID) minus Placebo matching BI 409306)",
                            "otherAnalysisDescription": "The mean difference is actually adjusted mean of difference and the dispersion value is standard error of differences"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) Total Score After 12-week Treatment",
                    "description": "The CDR-SB is obtained through semi-structured interviews of patients and informants, and cognitive functioning was rated in 6 domains of functioning: memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care.\n\nEach domain was rated on a 5-point scale of functioning as follows: 0-no impairment; 0.5-questionable impairment; 1-mild impairment; 2-moderate impairment and 3-severe impairment. Only personal care was scored on a 4-point scale without a 0.5 rating available. The higher the score, the greater the severity of dementia. Least Squares Mean is actually an adjusted mean change from baseline.",
                    "populationDescription": "FAS- Observed cases",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Unit on scale",
                    "timeFrame": "Baseline and 12 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "BI 409306 10 Milligram (mg) Once Daily (QD)",
                            "description": "Patients were administered orally a tablet of 10 mg BI 409306 once daily for 12 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "BI 409306 25 mg QD",
                            "description": "Patients were administered orally a tablet of 25 mg BI 409306 once daily for 12 weeks."
                        },
                        {
                            "id": "OG002",
                            "title": "BI 409306 50 mg QD",
                            "description": "Patients were administered orally a tablet of 50 mg BI 409306 once daily for 12 weeks."
                        },
                        {
                            "id": "OG003",
                            "title": "BI 409306 25 mg Twice Daily (BID)",
                            "description": "Patients were administered orally a tablet of 25 mg BI 409306 twice daily for 12 weeks."
                        },
                        {
                            "id": "OG004",
                            "title": "Placebo Matching BI 409306",
                            "description": "Patients were administered orally Placebo matching 10 mg/25 mg/ 50 mg BI 409306 for 12 weeks"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "21"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "19"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "16"
                                },
                                {
                                    "groupId": "OG003",
                                    "value": "18"
                                },
                                {
                                    "groupId": "OG004",
                                    "value": "40"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.0",
                                            "spread": "0.19"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.4",
                                            "spread": "0.20"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "-0.1",
                                            "spread": "0.22"
                                        },
                                        {
                                            "groupId": "OG003",
                                            "value": "0.1",
                                            "spread": "0.21"
                                        },
                                        {
                                            "groupId": "OG004",
                                            "value": "0.1",
                                            "spread": "0.14"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG004"
                            ],
                            "groupDescription": "Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.",
                            "nonInferiorityType": "SUPERIORITY",
                            "pValue": "0.9491",
                            "pValueComment": "p-value was nominal and not adjusted.",
                            "statisticalMethod": "Mixed Model Repeated Measurement (MMRM)",
                            "statisticalComment": "Kenward-Roger was used to model degrees of freedom.",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.0",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.49",
                            "ciUpperLimit": "0.46",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.24",
                            "estimateComment": "Mean difference (BI 409306 10 milligram (mg) once daily (QD) minus Placebo matching BI 409306)",
                            "otherAnalysisDescription": "The mean difference is actually adjusted mean of difference and the dispersion value is standard error of differences."
                        },
                        {
                            "groupIds": [
                                "OG001",
                                "OG004"
                            ],
                            "groupDescription": "Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.",
                            "nonInferiorityType": "SUPERIORITY",
                            "pValue": "0.1699",
                            "pValueComment": "p-value was nominal and not adjusted.",
                            "statisticalMethod": "Mixed Model Repeated Measurement (MMRM)",
                            "statisticalComment": "Kenward-Roger was used to model degrees of freedom.",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.3",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.15",
                            "ciUpperLimit": "0.84",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.25",
                            "estimateComment": "Mean difference (BI 409306 25 mg QD minus Placebo matching BI 409306)",
                            "otherAnalysisDescription": "The mean difference is actually adjusted mean of difference and the dispersion value is standard error of differences."
                        },
                        {
                            "groupIds": [
                                "OG002",
                                "OG004"
                            ],
                            "groupDescription": "Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.",
                            "nonInferiorityType": "SUPERIORITY",
                            "pValue": "0.4948",
                            "pValueComment": "p-value was nominal and not adjusted.",
                            "statisticalMethod": "Mixed Model Repeated Measurement (MMRM)",
                            "statisticalComment": "Kenward-Roger was used to model degrees of freedom.",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.2",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.69",
                            "ciUpperLimit": "0.33",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.26",
                            "estimateComment": "Mean difference (BI 409306 50 mg QD minus Placebo matching BI 409306)",
                            "otherAnalysisDescription": "The mean difference is actually adjusted mean of difference and the dispersion value is standard error of differences"
                        },
                        {
                            "groupIds": [
                                "OG003",
                                "OG004"
                            ],
                            "groupDescription": "Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.",
                            "nonInferiorityType": "SUPERIORITY",
                            "pValue": "0.7548",
                            "pValueComment": "p-value was nominal and not adjusted.",
                            "statisticalMethod": "Mixed Model Repeated Measurement (MMRM)",
                            "statisticalComment": "Kenward-Roger was used to model degrees of freedom.",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.1",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.42",
                            "ciUpperLimit": "0.58",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.25",
                            "estimateComment": "Mean difference (BI 409306 25 mg twice daily (BID) minus Placebo matching BI 409306)",
                            "otherAnalysisDescription": "The mean difference is actually adjusted mean of difference and the dispersion value is standard error of differences"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog11) Total Score After 12-week Treatment",
                    "description": "Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog11) is an 11-item cognitive subscale that objectively measures memory, language, orientation, and praxis with a total score range of 0 to 70. The greater the dysfunction, the greater the score. Least Squares Mean is actually an adjusted mean change from baseline.",
                    "populationDescription": "FAS- Observed cases",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Unit on scale",
                    "timeFrame": "Baseline and 12 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "BI 409306 10 Milligram (mg) Once Daily (QD)",
                            "description": "Patients were administered orally a tablet of 10 mg BI 409306 once daily for 12 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "BI 409306 25 mg QD",
                            "description": "Patients were administered orally a tablet of 25 mg BI 409306 once daily for 12 weeks."
                        },
                        {
                            "id": "OG002",
                            "title": "BI 409306 50 mg QD",
                            "description": "Patients were administered orally a tablet of 50 mg BI 409306 once daily for 12 weeks."
                        },
                        {
                            "id": "OG003",
                            "title": "BI 409306 25 mg Twice Daily (BID)",
                            "description": "Patients were administered orally a tablet of 25 mg BI 409306 twice daily for 12 weeks."
                        },
                        {
                            "id": "OG004",
                            "title": "Placebo Matching BI 409306",
                            "description": "Patients were administered orally Placebo matching 10 mg/25 mg/ 50 mg BI 409306 for 12 weeks"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "19"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "17"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "19"
                                },
                                {
                                    "groupId": "OG003",
                                    "value": "19"
                                },
                                {
                                    "groupId": "OG004",
                                    "value": "38"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.98",
                                            "spread": "0.885"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.62",
                                            "spread": "0.935"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "0.12",
                                            "spread": "0.875"
                                        },
                                        {
                                            "groupId": "OG003",
                                            "value": "-1.27",
                                            "spread": "0.875"
                                        },
                                        {
                                            "groupId": "OG004",
                                            "value": "1.24",
                                            "spread": "0.619"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG004"
                            ],
                            "groupDescription": "The dependent variable was the change from the baseline score at Week 12. The model included fixed, categorical covariates of treatment as well as fixed continuous covariates of baseline score.",
                            "nonInferiorityType": "SUPERIORITY",
                            "nonInferiorityComment": "Analyses of covariance (ANCOVA) were used to assess between-group differences in the modelled changes from baseline to Week 12.",
                            "pValue": "0.8137",
                            "pValueComment": "p-value was nominal and not adjusted.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.26",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-2.40",
                            "ciUpperLimit": "1.89",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "1.081",
                            "estimateComment": "Mean difference (BI 409306 10 milligram (mg) once daily (QD) minus Placebo matching BI 409306)",
                            "otherAnalysisDescription": "The mean difference is actually adjusted mean of difference and the dispersion value is standard error of differences."
                        },
                        {
                            "groupIds": [
                                "OG001",
                                "OG004"
                            ],
                            "groupDescription": "The dependent variable was the change from the baseline score at Week 12. The model included fixed, categorical covariates of treatment as well as fixed continuous covariates of baseline score.",
                            "nonInferiorityType": "SUPERIORITY",
                            "nonInferiorityComment": "Analyses of covariance (ANCOVA) were used to assess between-group differences in the modelled changes from baseline to Week 12.",
                            "pValue": "0.5801",
                            "pValueComment": "p-value was nominal and not adjusted.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.62",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-2.84",
                            "ciUpperLimit": "1.60",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "1.120",
                            "estimateComment": "Mean difference (BI 409306 25 mg QD minus Placebo matching BI 409306)",
                            "otherAnalysisDescription": "The mean difference is actually adjusted mean of difference and the dispersion value is standard error of differences."
                        },
                        {
                            "groupIds": [
                                "OG002",
                                "OG004"
                            ],
                            "groupDescription": "The dependent variable was the change from the baseline score at Week 12. The model included fixed, categorical covariates of treatment as well as fixed continuous covariates of baseline score.",
                            "nonInferiorityType": "SUPERIORITY",
                            "nonInferiorityComment": "Analyses of covariance (ANCOVA) were used to assess between-group differences in the modelled changes from baseline to Week 12.",
                            "pValue": "0.2978",
                            "pValueComment": "p-value was nominal and not adjusted.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-1.12",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-3.25",
                            "ciUpperLimit": "1.00",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "1.072",
                            "estimateComment": "Mean difference (BI 409306 50 mg QD minus Placebo matching BI 409306)",
                            "otherAnalysisDescription": "The mean difference is actually adjusted mean of difference and the dispersion value is standard error of differences"
                        },
                        {
                            "groupIds": [
                                "OG003",
                                "OG004"
                            ],
                            "groupDescription": "The dependent variable was the change from the baseline score at Week 12. The model included fixed, categorical covariates of treatment as well as fixed continuous covariates of baseline score.",
                            "nonInferiorityType": "SUPERIORITY",
                            "nonInferiorityComment": "Analyses of covariance (ANCOVA) were used to assess between-group differences in the modelled changes from baseline to Week 12.",
                            "pValue": "0.0209",
                            "pValueComment": "p-value was nominal and not adjusted.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-2.51",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-4.64",
                            "ciUpperLimit": "-0.39",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "1.072",
                            "estimateComment": "Mean difference (BI 409306 25 mg twice daily (BID) minus Placebo matching BI 409306)",
                            "otherAnalysisDescription": "The mean difference is actually adjusted mean of difference and the dispersion value is standard error of differences"
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment From Two Twin Trials, Present 1289.5 (NCT02240693) and 1289.7 (NCT02337907)",
                    "description": "Neuropsychological Test Battery (NTB) response, defined as change from baseline in total z-score after 12 weeks of treatment. The NTB Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean at baseline. Negative numbers indicate values lower than baseline and positive numbers indicate values higher than baseline. Change from baseline will be calculated as the post-baseline composite z-score minus the pre-treatment z-score, such that a positive change indicates an improvement from baseline",
                    "populationDescription": "FAS observed cases for pooled groups of these twin trials",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "z-score",
                    "timeFrame": "Baseline and 12 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "BI 409306 10 Milligram (mg) Once Daily (QD)",
                            "description": "Patients were administered orally a tablet of 10 mg BI 409306 once daily for 12 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "BI 409306 25 mg QD",
                            "description": "Patients were administered orally a tablet of 25 mg BI 409306 once daily for 12 weeks."
                        },
                        {
                            "id": "OG002",
                            "title": "BI 409306 50 mg QD",
                            "description": "Patients were administered orally a tablet of 50 mg BI 409306 once daily for 12 weeks."
                        },
                        {
                            "id": "OG003",
                            "title": "BI 409306 25 mg Twice Daily (BID)",
                            "description": "Patients were administered orally a tablet of 25 mg BI 409306 twice daily for 12 weeks."
                        },
                        {
                            "id": "OG004",
                            "title": "Pooled BI 409306",
                            "description": "Patients were administered orally a tablet of BI 409306 (10 mg, 25 mg, 50 mg once daily and 25 mg twice daily)for 12 weeks."
                        },
                        {
                            "id": "OG005",
                            "title": "Placebo Matching BI 409306",
                            "description": "Patients were administered orally Placebo matching 10 mg/25 mg/ 50 mg BI 409306 for 12 weeks"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "67"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "63"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "67"
                                },
                                {
                                    "groupId": "OG003",
                                    "value": "63"
                                },
                                {
                                    "groupId": "OG004",
                                    "value": "260"
                                },
                                {
                                    "groupId": "OG005",
                                    "value": "122"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.20",
                                            "spread": "0.046"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.19",
                                            "spread": "0.048"
                                        },
                                        {
                                            "groupId": "OG002",
                                            "value": "0.19",
                                            "spread": "0.046"
                                        },
                                        {
                                            "groupId": "OG003",
                                            "value": "0.10",
                                            "spread": "0.047"
                                        },
                                        {
                                            "groupId": "OG004",
                                            "value": "0.17",
                                            "spread": "0.025"
                                        },
                                        {
                                            "groupId": "OG005",
                                            "value": "0.19",
                                            "spread": "0.035"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG005"
                            ],
                            "groupDescription": "Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, current Acetylcholine Esterase Inhibitor (AChEI) use (Yes, No), and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.\n\nThe study identifier is also a categorical covariate for the twin studies analyses.",
                            "nonInferiorityType": "SUPERIORITY",
                            "nonInferiorityComment": "H0: The dose group with the peak response in the respective model Mean NTB response = Mean NTB response of placebo.",
                            "pValue": "0.8694",
                            "pValueComment": "p-value was nominal and not adjusted.",
                            "statisticalMethod": "Mixed Model Repeated Measurement (MMRM)",
                            "statisticalComment": "Kenward-Roger was used to model degrees of freedom.",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.01",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.101",
                            "ciUpperLimit": "0.120",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.056",
                            "estimateComment": "Mean difference (BI 409306 10 milligram (mg) once daily (QD) minus Placebo matching BI 409306)",
                            "otherAnalysisDescription": "The mean difference is actually adjusted mean of difference and the dispersion value is standard error of differences."
                        },
                        {
                            "groupIds": [
                                "OG001",
                                "OG005"
                            ],
                            "groupDescription": "Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, current Acetylcholine Esterase Inhibitor (AChEI) use (Yes, No), and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.\n\nThe study identifier is also a categorical covariate for the twin studies analyses.",
                            "nonInferiorityType": "SUPERIORITY",
                            "nonInferiorityComment": "H0: The dose group with the peak response in the respective model Mean NTB response = Mean NTB response of placebo.",
                            "pValue": "0.9512",
                            "pValueComment": "p-value was nominal and not adjusted.",
                            "statisticalMethod": "Mixed Model Repeated Measurement (MMRM)",
                            "statisticalComment": "Kenward-Roger was used to model degrees of freedom.",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.00",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.116",
                            "ciUpperLimit": "0.109",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.057",
                            "estimateComment": "Mean difference (BI 409306 25 mg QD minus Placebo matching BI 409306)",
                            "otherAnalysisDescription": "The mean difference is actually adjusted mean of difference and the dispersion value is standard error of differences."
                        },
                        {
                            "groupIds": [
                                "OG002",
                                "OG005"
                            ],
                            "groupDescription": "Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, current Acetylcholine Esterase Inhibitor (AChEI) use (Yes, No), and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.\n\nThe study identifier is also a categorical covariate for the twin studies analyses.",
                            "nonInferiorityType": "SUPERIORITY",
                            "nonInferiorityComment": "H0: The dose group with the peak response in the respective model Mean NTB response = Mean NTB response of placebo.",
                            "pValue": "0.9321",
                            "pValueComment": "p-value was nominal and not adjusted.",
                            "statisticalMethod": "Mixed Model Repeated Measurement (MMRM)",
                            "statisticalComment": "Kenward-Roger was used to model degrees of freedom.",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.00",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.105",
                            "ciUpperLimit": "0.115",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.056",
                            "estimateComment": "Mean difference (BI 409306 50 mg QD minus Placebo matching BI 409306)",
                            "otherAnalysisDescription": "The mean difference is actually adjusted mean of difference and the dispersion value is standard error of differences"
                        },
                        {
                            "groupIds": [
                                "OG003",
                                "OG005"
                            ],
                            "groupDescription": "Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, current Acetylcholine Esterase Inhibitor (AChEI) use (Yes, No), and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.\n\nThe study identifier is also a categorical covariate for the twin studies analyses.",
                            "nonInferiorityType": "SUPERIORITY",
                            "nonInferiorityComment": "H0: The dose group with the peak response in the respective model Mean NTB response = Mean NTB response of placebo.",
                            "pValue": "0.1288",
                            "pValueComment": "p-value was nominal and not adjusted.",
                            "statisticalMethod": "Mixed Model Repeated Measurement (MMRM)",
                            "statisticalComment": "Kenward-Roger was used to model degrees of freedom.",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.09",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.199",
                            "ciUpperLimit": "0.025",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.057",
                            "estimateComment": "Mean difference (BI 409306 25 mg twice daily (BID) minus Placebo matching BI 409306)",
                            "otherAnalysisDescription": "The mean difference is actually adjusted mean of difference and the dispersion value is standard error of differences"
                        },
                        {
                            "groupIds": [
                                "OG004",
                                "OG005"
                            ],
                            "groupDescription": "Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, current Acetylcholine Esterase Inhibitor (AChEI) use (Yes, No), and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction. The study identifier is also a categorical covariate for the twin studies analyses.",
                            "nonInferiorityType": "SUPERIORITY",
                            "nonInferiorityComment": "H0: The dose group with the peak response in the respective model Mean NTB response = Mean NTB response of placebo.",
                            "pValue": "0.6492",
                            "pValueComment": "p-value was nominal and not adjusted.",
                            "statisticalMethod": "Mixed Model Repeated Measurement (MMRM)",
                            "statisticalComment": "Kenward-Roger was used to model degrees of freedom.",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.02",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.098",
                            "ciUpperLimit": "0.061",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.041",
                            "estimateComment": "Mean difference (Pooled BI 409306 minus Placebo matching BI 409306)",
                            "otherAnalysisDescription": "The mean difference is actually adjusted mean of difference and the dispersion value is standard error of differences"
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "5",
            "timeFrame": "From the first dose of study medication until 7 days after last administration of BI 409306, up to 16 weeks.",
            "description": "The treated set (TS) used (all patients who were randomised and treated with at least one dose of trial medication.) for safety assessment.",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "BI 409306 10 Milligram (mg) Once Daily (QD)",
                    "description": "Patients were administered orally a tablet of 10 mg BI 409306 once daily for 12 weeks.",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 22,
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 22,
                    "otherNumAffected": 5,
                    "otherNumAtRisk": 22
                },
                {
                    "id": "EG001",
                    "title": "BI 409306 25 mg QD",
                    "description": "Patients were administered orally a tablet of 25 mg BI 409306 once daily for 12 weeks.",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 21,
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 21,
                    "otherNumAffected": 8,
                    "otherNumAtRisk": 21
                },
                {
                    "id": "EG002",
                    "title": "BI 409306 50 mg QD",
                    "description": "Patients were administered orally a tablet of 50 mg BI 409306 once daily for 12 weeks.",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 21,
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 21,
                    "otherNumAffected": 11,
                    "otherNumAtRisk": 21
                },
                {
                    "id": "EG003",
                    "title": "BI 409306 25 mg Twice Daily (BID)",
                    "description": "Patients were administered orally a tablet of 25 mg BI 409306 twice daily for 12 weeks.",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 21,
                    "seriousNumAffected": 1,
                    "seriousNumAtRisk": 21,
                    "otherNumAffected": 3,
                    "otherNumAtRisk": 21
                },
                {
                    "id": "EG004",
                    "title": "Placebo Matching BI 409306",
                    "description": "Patients were administered orally tablet of Placebo matching BI 409306 once daily for 12 weeks.",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 43,
                    "seriousNumAffected": 1,
                    "seriousNumAtRisk": 43,
                    "otherNumAffected": 6,
                    "otherNumAtRisk": 43
                }
            ],
            "seriousEvents": [
                {
                    "term": "Abdominal pain",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG004",
                            "numAffected": 1,
                            "numAtRisk": 43
                        }
                    ]
                },
                {
                    "term": "Haematuria",
                    "organSystem": "Renal and urinary disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG004",
                            "numAffected": 0,
                            "numAtRisk": 43
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Bradycardia",
                    "organSystem": "Cardiac disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 3,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG004",
                            "numAffected": 0,
                            "numAtRisk": 43
                        }
                    ]
                },
                {
                    "term": "Vision blurred",
                    "organSystem": "Eye disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 3,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG004",
                            "numAffected": 0,
                            "numAtRisk": 43
                        }
                    ]
                },
                {
                    "term": "Back pain",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 2,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG004",
                            "numAffected": 0,
                            "numAtRisk": 43
                        }
                    ]
                },
                {
                    "term": "Muscle spasms",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG004",
                            "numAffected": 0,
                            "numAtRisk": 43
                        }
                    ]
                },
                {
                    "term": "Headache",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 4,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 3,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG004",
                            "numAffected": 2,
                            "numAtRisk": 43
                        }
                    ]
                },
                {
                    "term": "Rash",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 2,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG004",
                            "numAffected": 0,
                            "numAtRisk": 43
                        }
                    ]
                },
                {
                    "term": "Hypertension",
                    "organSystem": "Vascular disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 4,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 21
                        },
                        {
                            "groupId": "EG004",
                            "numAffected": 4,
                            "numAtRisk": 43
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictionType": "OTHER",
                "restrictiveAgreement": true,
                "otherDetails": "Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights."
            },
            "pointOfContact": {
                "title": "Boehringer Ingelheim, Call Center",
                "organization": "Boehringer Ingelheim",
                "email": "clintriage.rdg@boehringer-ingelheim.com",
                "phone": "1-800-243-0127"
            }
        }
    },
    "target_category": "Cognitive enhancer",
    "drug": [
        "BI 409306 (oral small\u2011molecule PDE9A inhibitor)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: BI 409306 is a potent, selective phosphodiesterase\u20119A (PDE9A) inhibitor \u2014 a small\u2011molecule intended to increase cGMP, promote synaptic plasticity and improve memory/cognition rather than to remove amyloid or tau pathology. \ue200cite\ue202turn0search3\ue202turn0search8\ue201",
        "Act: The trial description (oral BI 409306, four dose levels vs placebo, 12\u2011week treatment, cognitive endpoints such as the Neuropsychological Test Battery/ADAS\u2011Cog/CDR\u2011SB) matches published Phase II studies testing BI 409306 for symptomatic cognitive improvement in prodromal/mild Alzheimer\u2019s disease. These studies evaluated cognitive outcomes and did not target amyloid or tau directly. \ue200cite\ue202turn0search2\ue202turn0search3\ue201",
        "Reflect: Given the intervention is a small\u2011molecule PDE9A inhibitor developed to enhance cognition (mechanism: raise cGMP and facilitate synaptic plasticity) and the trial endpoints are cognitive/symptomatic, the appropriate category is 'Cognitive enhancer' rather than a disease\u2011targeted biologic or disease\u2011targeted small molecule. Published pooled Phase II results showed no significant cognitive benefit but confirm the drug\u2019s intended use as a symptomatic cognitive enhancer. \ue200cite\ue202turn0search3\ue202turn0search0\ue201",
        "Web search sources used (key results): (1) Pooled Phase II report (Alzheimer\u2019s Research & Therapy / PMC) describing 12\u2011week, multi\u2011dose oral BI 409306 trials in prodromal/mild AD and negative efficacy results. \ue200cite\ue202turn0search3\ue201 (2) PubMed abstract summarizing the Phase II studies and endpoints. \ue200cite\ue202turn0search0\ue201 (3) Phase I proof\u2011of\u2011mechanism study showing BI 409306 increases CSF cGMP (target engagement). \ue200cite\ue202turn0search1\ue201 (4) Preclinical study demonstrating increased brain cGMP, enhanced LTP and improved memory in rodents (supports cognitive\u2011enhancer mechanism). \ue200cite\ue202turn0search8\ue201 (5) Phase I safety/PK overview describing BI 409306 as a selective PDE9A inhibitor. \ue200cite\ue202turn0search5\ue201"
    ],
    "agent_type": "M) Synaptic Plasticity/Neuroprotection",
    "explanation_agent": [
        "Reason: BI 409306 is a selective phosphodiesterase\u20119A (PDE9A) inhibitor designed to raise cGMP and enhance synaptic signaling/plasticity to improve memory/cognition (a symptomatic cognitive\u2011enhancer mechanism), not to target amyloid, tau, ApoE, vasculature, etc. \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "Act: Extracted details \u2014 oral small\u2011molecule BI 409306 (PDE9A inhibitor), 12\u2011week randomized studies with cognitive endpoints (NTB, ADAS\u2011Cog, CDR\u2011SB) testing symptomatic cognitive benefit rather than amyloid/tau removal. These Phase II studies pooled 457 patients and showed no cognitive benefit but confirm the intended synaptic\u2011plasticity/cognitive\u2011enhancer mechanism. \ue200cite\ue202turn0search3\ue202turn0search1\ue201",
        "Reflect: Mapping to CADRO, the intervention\u2019s primary biological focus is enhancing synaptic function/plasticity (increase cGMP, facilitate LTP and cognition), which corresponds to M) Synaptic Plasticity/Neuroprotection. The classification excludes disease\u2011modifying categories (A/B/I etc.) because the mechanism is symptomatic/signal\u2011modifying. Program discontinuation reports and full publications corroborate this interpretation. \ue200cite\ue202turn0search5\ue202turn0search3\ue201",
        "Web search results (key sources used): (1) Phase I proof\u2011of\u2011mechanism showing BI 409306 increases CSF cGMP (target engagement). \ue200cite\ue202turn0search0\ue201 (2) PubMed entry summarizing the two Phase II RCTs in prodromal/mild AD (design/mechanism). \ue200cite\ue202turn0search1\ue201 (3) Full pooled Phase II report (Alzheimer\u2019s Research & Therapy) with endpoints, 12\u2011week treatment, and negative efficacy results. \ue200cite\ue202turn0search3\ue201 (4) Industry coverage noting BI 409306 was intended to restore signaling/glutamatergic circuit function (symptomatic approach) and program wind\u2011down after negative results. \ue200cite\ue202turn0search5\ue201"
    ]
}